DSIP (delta sleep inducing peptide or delta sleep peptide) was first discovered in 1974 by the Swiss G. Schoeneberger and M. Monnier, who isolated it from the brain blood of sleeping rabbits. Since the discovery, several hundred articles have been published, most of which describe the localization and involvement of the peptide in the brain and peripheral nervous system. The main property of DSIP is the ability to induce a stage of non-REM sleep, which is effective in combating insomnia. The peptide was found to affect electrophysiological activity, neurotransmitter levels in the brain, circadian and locomotor structures, hormonal levels, psychological performance and concentration, and the activity of neuropharmacological drugs. A pronounced effect on withdrawal symptoms, including pain conditions in alcoholics and drug addicts, was noted. It has also been shown to be effective in chronic pain, including migraines.

The results of various research groups have shown that DSIP has a wide range of pharmacological actions:

Neuroprotective
Anti-stress
Antioxidant
Anticonvulsant
Antihypoxic
Antitoxic
Geroprotective
In Russia, based on the peptide, a drug is registered - Deltaran. Indications for the use of Deltaran are as follows:

Treatment and prevention of stress-induced conditions
Alcohol withdrawal syndrome and primary pathological craving for alcohol
Quantity: 5 mg

Purity: over 97%

Form: lyophilizate

Excipient: mannitol

Storage: no more than +5C